Gland Pharma Q1 FY27: PAT rises 47 percent to Rs 3,170 mn

Pat Growth 25pctEbitda Margin ExpansionResults View source PDF Explain this filing

GLAND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+9.6%Reaction day

₹2670.00

prior close

₹2845.50

announcement price

After-mkt

timing

Nifty Smallcap 250market+0.2%+9.4% vs market

Pharmaceuticals peers, median of 164sector+0.1%+9.5% vs sector

On the reaction day the stock moved 9.4 pts more than Nifty Smallcap 250 and 9.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.6

10m

+2.1

15m

+2.6

30m

+4.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+9.6+0.2+9.4+0.1+9.5

Next day

+7.9-0.1+7.9-0.5+8.3

+11.0+0.1+10.9+0.1+10.9

+11.1-0.4+11.4-0.5+11.6

+8.7-0.2+8.9-1.1+9.8

+6.9+0.0+6.9-0.7+7.7

+6.7-0.0+6.7-1.2+7.9

15d

+8.0+0.1+7.9-0.8+8.8

+9.7-0.0+9.7+0.9+8.7

+15.5-3.1+18.7-3.1+18.6

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 164Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Gland Pharma posted Q1 FY27 consolidated revenue from operations of Rs 18,003 mn, up nearly 20 percent from Rs 15,056 mn YoY. PAT jumped 47 percent to Rs 3,170 mn from Rs 2,155 mn. Total income stood at Rs 18,615 mn. Basic EPS rose to Rs 19.23 from Rs 13.08. Deloitte Haskins and Sells issued an unmodified limited review report. Results include subsidiaries across Singapore, USA, France, and Belgium.

Likely market impact

Strong 47 percent PAT growth signals margin expansion YoY. EPS up from Rs 13.08 to Rs 19.23. Clean audit report. Positive for shareholders.